TECH vs. NBIX, QGEN, RGEN, CRSP, DNLI, A, MTD, WAT, ILMN, and CRL
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), and Charles River Laboratories International (CRL).
Bio-Techne (NASDAQ:TECH) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Neurocrine Biosciences has a net margin of 18.65% compared to Bio-Techne's net margin of 17.59%. Neurocrine Biosciences' return on equity of 17.45% beat Bio-Techne's return on equity.
99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.5% of Bio-Techne shares are held by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Bio-Techne presently has a consensus price target of $81.00, suggesting a potential upside of 4.94%. Neurocrine Biosciences has a consensus price target of $150.85, suggesting a potential upside of 11.40%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Neurocrine Biosciences received 597 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
Bio-Techne has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
In the previous week, Neurocrine Biosciences had 14 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 9 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.95 beat Neurocrine Biosciences' score of 0.65 indicating that Bio-Techne is being referred to more favorably in the media.
Bio-Techne has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Summary
Neurocrine Biosciences beats Bio-Techne on 12 of the 19 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
